Healthcare surged in June. Raymond James is adding these two dividend payers to list of top picks

Healthcare rallied in June (+6% as investors rotated into defensives) and Raymond James added UnitedHealth (UNH) and Janus Living (JAN) as top picks. UNH is up 28% YTD and Raymond James cites upside ahead of its July 16 earnings, pointing to moderating medical costs and improving insurance/Optum margins; the stock also raised its dividend 5% to $2.32/share (2.2% yield). JAN, a new IPO at $20 (valued at $840M) now trading at $28.99 (+45% since IPO), is recommended on improving seniors-housing fundamentals and dividends (1.96% yield), though the consensus price target implies only ~3% upside.

Analysis

The cleaner expression here is not “healthcare is defensive,” but that earnings revision breadth is finally turning in favor of the group after a long period where multiple expansion came from scarcity value alone. UNH is the highest-quality way to play that shift because the market is still underpricing how much incremental margin improvement in managed care and care-delivery businesses can lever through to EPS; if July results confirm lower medical cost trend, the stock can rerate even without heroic revenue growth. The near-term risk is that the consensus is already leaning into this setup, so a miss on cost trend or a conservative 2H guide would matter more than the headline beat.

JAN is a different trade: it is less about “defensive rotation” and more about a supply-constrained operating model in senior housing. The structural setup is favorable for months to years if occupancy keeps recovering and new supply remains muted, but the stock has already moved hard post-IPO, so the easy money may have been captured. Second-order, stronger public comps could tighten acquisition pricing across the fragmented senior housing universe, pressuring cap rates for private operators and benefiting scaled platforms that can source deals cheaply.

The contrarian miss is that both names are now consensus-safe. In a tape where factor leadership can rotate quickly, healthcare can lose relative performance as soon as tech momentum stabilizes or rates stop falling. The real falsifier for UNH is a July report that does not show further margin recovery; for JAN, it is any evidence that occupancy gains are slowing before acquisition synergies show up. In that case, the sector’s recent outperformance would likely compress back toward defensiveness rather than quality growth.

Key Decisions for Investors

• Long UNH into the July 16 earnings window; add on any pre-earnings pullback, with a 1-2 month target of 5-8% if medical cost commentary confirms moderation. Falsifier: unchanged or higher medical loss ratio / flat FY guidance.
• Use UNH as a pair trade vs a high-multiple defensive-to-growth crossover that is more rate-sensitive, or simply against OSCR on a relative basis: long UNH / short OSCR for 1-3 months to express quality plus estimate-upgrade momentum. Falsifier: OSCR prints accelerating membership growth with improving loss ratios.
• Watch JAN rather than chase: current setup supports a hold/buy-on-dip only if the stock pulls back toward the IPO anchor zone and operating metrics validate. Upside is probably mid-single digits from here unless occupancy and margin expansion surprise. Falsifier: occupancy stalls or acquisition pricing turns less accretive.
• If looking for sector exposure, prefer a healthcare ETF basket tilt (XLV) with overweight UNH rather than a broad healthcare long; this reduces idiosyncratic execution risk while preserving the revision-cycle trade for the next quarter.